A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group by Abernethy, Amy Pickar et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
This is a copy of an article published in the Journal of 
Palliative Medicine, © 2010 copyright Mary Ann Liebert, Inc.; 
the Journal of Palliative Medicine is available online at: 
http://online.liebertpub.com 
Please cite this as: Abernethy, A.P., Aziz, N.M., Basch, E., Bull, 
J., Cleeland, C.S., Currow, D.C., Fairclough, D., Hanson, L., 
Hauser, J., Ko, D., Lloyd, L., Morrison, R.S., Otis-Green, S., 
Pantilat, S., Portenoy, R.K., Ritchie, C., Rocker, G., Wheeler, 
J.L., Zafar, S.Y. and Kutner, J.S., 2010. A strategy to advance 
the evidence base in palliative medicine: formation of a 
palliative care research cooperative group. Journal of 
Palliative Medicine, 13(12), 1407-1413.  
doi:10.1089/jpm.2010.0261 
© 2010 Mary Ann Liebert, Inc. Published version reproduced 
here in accordance with the policy of the publisher. 
Special Report
A Strategy To Advance the Evidence Base
in Palliative Medicine:
Formation of a Palliative Care Research Cooperative Group
Amy P. Abernethy, M.D.,1,2 Noreen M. Aziz, M.D., Ph.D., M.P.H.,3 Ethan Basch, M.D.,4 Janet Bull, M.D.,5
Charles S. Cleeland, Ph.D.,6 David C. Currow, B.Med., M.P.H.,7,8 Diane Fairclough, Dr.P.H.,9
Laura Hanson, M.D., M.P.H.,10 Joshua Hauser, M.D.,11 Danielle Ko, MBBS, L.L.B.,12 Linda Lloyd, Dr.P.H.,13
R. Sean Morrison, M.D.,14 Shirley Otis-Green, M.S.W., LCSW, ACSW, OSW-C,15 Steve Pantilat, M.D.,16
Russell K. Portenoy, M.D.,17 Christine Ritchie, M.D.,18 Graeme Rocker, M.D.,19
Jane L. Wheeler, MSPH,1 S. Yousuf Zafar, M.D., M.H.S.,1 and Jean S. Kutner, M.D., MSPH20
Abstract
Background: Palliative medicine has made rapid progress in establishing its scientific and clinical legitimacy, yet
the evidence base to support clinical practice remains deficient in both the quantity and quality of published
studies. Historically, the conduct of research in palliative care populations has been impeded by multiple
barriers including health care system fragmentation, small number and size of potential sites for recruitment,
vulnerability of the population, perceptions of inappropriateness, ethical concerns, and gate-keeping.
Methods: A group of experienced investigators with backgrounds in palliative care research convened to con-
sider developing a research cooperative group as a mechanism for generating high-quality evidence on prior-
itized, clinically relevant topics in palliative care.
Results: The resulting Palliative Care Research Cooperative (PCRC) agreed on a set of core principles: active,
interdisciplinary membership; commitment to shared research purposes; heterogeneity of participating sites;
development of research capacity in participating sites; standardization of methodologies, such as consenting
and data collection/management; agile response to research requests from government, industry, and investi-
gators; focus on translation; education and training of future palliative care researchers; actionable results that
can inform clinical practice and policy. Consensus was achieved on a first collaborative study, a randomized
clinical trial of statin discontinuation versus continuation in patients with a prognosis of less than 6 months who
are taking statins for primary or secondary prevention. This article describes the formation of the PCRC,
highlighting processes and decisions taken to optimize the cooperative group’s success.
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Introduction
Methodologically rigorous palliative
care research is needed
Extensive research activity has followed the recogni-tion of palliative medicine as a subspecialty; citation
trends and new publication channels reflect this collective
effort. Between 1970 and 2005, there has been a fourfold in-
crease in palliative care studies as a proportion of all Ovid
MEDLINE citations (0.1% versus 0.4%). Palliative care clinical
trials comprised 1% of all palliative care literature in 1970; this
percentage rose to 7% during 2001–2005. Palliative care clin-
ical trials as a percentage of all clinical trials rose from 0.2% in
1970 to 0.8% in 2001–2005.1 The International Association of
Hospice and Palliative Care website now lists 38 journals
specifically dedicated to hospice, palliative, and end-of-life
care2; increasingly, palliative care-relevant articles are pub-
lished in general medical, nursing, and social work journals.
Despite a greater volume of published palliative care
studies, the majority of palliative care evidence is not derived
from randomized controlled trials or other methodologically
rigorous studies. While it is possible that other study designs
are more appropriate to the palliative care setting, most pal-
liative care articles report case series or nonrandomized trials,
creating an imbalance in the sorts of research conducted in
this field. A study examining palliative care research articles
published from 2003–2005 identified 388 original articles, 8%
of which were randomized controlled trials (RCTs) and 2% of
which were controlled clinical trials.3
Prominent entities, such as the Institute ofMedicine (IOM)4,5
and National Institutes of Health (NIH),6 have recommended
that palliative care research become a national priority in
the United States. Many opportunities remain, however, to
improve the evidence underlying clinical practice in palliative
care and thus to provide more effective patient care. Multiple
studies have shown that critical outcomes in palliative care—
for example, pain control—have not improved.1,7,8–10 Poor
symptom controlmay result from inadequacies in care delivery
and/or from ineffective clinical management; a more solid
evidence base and an effective knowledge translation strategy
should remediate this problem.
Perceived barriers to palliative care research
Multiple barriers have deterred clinical trials in palliative
care. The population is vulnerable due to symptom and dis-
ease burden, psychological and social stressors, and condi-
tions impairing capacity to consent; this vulnerability raises
ethical concerns as well as feasibility issues related to research
conduct. Fragmentation of the health care system creates
problems related to loss to follow-up, data heterogeneity, and
nonstandardized procedures. Many provider sites are small
and community-based; although clinically proficient, they
lack resources, research-relevant skills, and substantial pop-
ulations for recruitment. Clinicians and caregivers, perceiving
research as an intrusion on the sanctity of the end of life, often
‘‘shield’’ patients from research staff.11
Standardized research methodologies are virtually nonexis-
tent in palliative care, a field which has historically pursued the
‘‘art ofmedicine,’’ orienting itself more toward compassion than
science; this false dichotomy has inhibited research. Uniform
research infrastructure, including data collection and manage-
ment processes, have yet to be instituted across palliative care
organizations interested in research. Researchers must battle
various antiresearch attitudes in palliative care, such as a belief
that research is incompatible with the goals of care.12,13
Additionally, palliative care is inherently interdisciplinary
and multidisciplinary; in practice, it entails collaboration
among specialists in medicine, nursing, chaplaincy and spir-
itual care, psychology, social work, andmedical ethics, aswell
as coordination across settings ranging from inpatient (hos-
pice, hospital) to outpatient (home, clinic, assisted living fa-
cility, nursing home). This complexity introduces challenges
into the conduct of research, such as the need to coordinate
differing research approaches, venues for data collection, and
regulatory bodies. Finally, funding for palliative care research
is scarce; federal investment is low, and palliative care grant
applications are thought to be poorly received and/or not
fully understood by NIH study sections.14
Cooperative groups in oncology
The cooperative group model, in which investigators work
together to conduct large-scale trials in multi-institutional
settings, may help overcome recognized barriers to research
in palliative care. In oncology, cooperative groups have
demonstrated remarkable success but they have also come
under intense scrutiny; a recent IOM report drew attention to
inefficiencies in and challenges faced by the National Cancer
Institute (NCI)-sponsored cooperative groups.15 Both the
successes and the shortcomings of existing cooperative
groups provide insights to inform future, collaborative, pal-
liative care research.
Potential for success through the cooperative group model
is perhaps best illustrated in pediatric oncology. The NCI has
funded cooperative groups in this area since 1956; in 2000,
four groups merged into a single Children’s Oncology Group
(COG). The dramatically improved outcomes for childhood
cancer patients—with overall 5-year survival rates increasing
from less than 30% in the 1960s to nearly 80% by the late
1990s16,17—can largely be attributed to the aggressive, coor-
dinated approach of the COG and its predecessors.18 By 1996,
pediatric cancer clinical trials cooperative groups provided
access to latest treatment protocols for nearly 95% of Ameri-
can cancer patients under the age of 15.19 With the COG’s
addition of an enhanced remote data entry system, enrollment
in COG clinical trials increased by 40%; in 2005, almost 90% of
the more than 11,000 newly diagnosed patients registered at
COG institutions were enrolled in a COG clinical trial.20
The NCI currently funds 10 cooperative groups to develop
and coordinate multi-institutional clinical trials, including the
Cancer and Leukemia Group B (CALGB), Eastern Co-
operative Oncology Group (ECOG), and American College of
Surgeons Oncology Group. Although the cooperative group
model is now well entrenched in oncology, its success in
streamlining adult cancer clinical trials is debatable. The 2010
IOM report mentioned above documented that the current
process of activating new Phase III clinical trials in NCI co-
operative groups averages more than 2 years, and of acti-
vating Phase I and II studies typically requires more than 500
days.15 Many trials, especially those that take longest to open,
close after failing to reach accrual goals; of all NCI-funded
Phase I–III trials that opened and closed between 2000–2007,
40%–50% failed to meet minimal accrual goals.21 The report
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found the activation path within cooperative groups to be
complex, requiringmany steps not critical to actual conduct of
the study.22
To elucidate the barriers faced by cooperative groups, Dilts
et al.23 carefully examined their function using the CALGB as
a case study. They identified four types of administrative
barriers to trial activation in oncology cooperative groups: (1)
procedural barriers, referring to policies or required steps,
e.g., that a cooperative group protocol be reviewed by an
external agency; (2) structural barriers, created by organiza-
tional design, e.g., sites performing research tasks in differing
orders; (3) infrastructural barriers, e.g., delays in protocol re-
view; and, (4) synchronicity barriers, i.e., requirements that
multiple steps come together before the study be launched.23
In subsequent work, Dilts and colleagues examined the pro-
cess of Phase III clinical trial development in the ECOG and
identified 481 distinct process steps required for study acti-
vation. Trial activation required a mean of 783 days from
executive approval and 808 days from initial conception.
Study development represented 44% of the total time neces-
sary for Phase II trial activation, and 54% of that for Phase III
trials. The most variable aspect of clinical trial development
was creation of study forms and preparation for data man-
agement, taking, on average, 401 days; compliance with
common data elements added another 114 days.24
The COG highlights the potential contribution that coop-
erative groups can make to scientific advancement and out-
comes improvement. Certain functions of cooperative groups,
such as combining patient populations to more efficiently
complete studies, make this structure well-suited to resolving
challenges encountered in palliative care research. The multi-
disciplinary nature of palliative care, and the diversity of care
venues including community-based and home settings, pres-
ent potential hurdles and care must be taken to avoid adding
layers of bureaucracy that slow the progress of research.24
Cooperative groups in palliative care
Successful research cooperative groupswith a palliative care
focus exist in Australia (Palliative Care Outcomes Collabora-
tive),25,26 Canada (Canadian Critical Care Trials Group),1,27
Europe (European Palliative Care Research Centre),28
and Sweden (Palliative Care Research Network in Sweden
[PANIS]).29 As yet, the United States does not have a palliative
care research cooperative group. The Population-based Pal-
liative Care ResearchNetwork (PoPCRN),30 a hospice practice-
based research network centered at the University of Colorado
Denver, offers a precedent for a multisite network devoted to
research in this field, though it has not regularly pursued
randomized clinical trials and lacks infrastructure for phar-
maceutical trials. A call to the discipline has underscored the
need for a U.S. cooperative group that can spark progress in
palliative care research similar to that of our international
colleagues.12
This article describes the formation of a new palliative care
research cooperative group, developed in light of the barriers
to research in this field and the challenges and opportunities
afforded by a cooperative group structure.
Methods
From 2005–2010, a group of senior palliative care investi-
gators, methodologists, and clinicians discussed how best to
advance the evidence base in palliative care, with an eye to-
ward developing a coordinated national research effort. In-
formal conversations culminated in a 1½-day meeting of
researchers interested in participating in the formation of a
palliative care cooperative group. Possessing expertise in
patient-reported outcomes, biostatistics, practice-based re-
search networks, social work, nursing, and psychology, par-
ticipants represented diverse clinical organizations, the NIH,
existing cooperative groups, and international palliative care
research networks. All participants funded most of their own
travel expenses; those unable to physically attend participated
via teleconference. The meeting was held on the University of
Colorado Denver Anschutz Medical Campus, January 16–17,
2010. Its purposes were to: (1) define the structure and func-
tion of a national interdisciplinary cooperative group in pal-
liative care research and (2) delineate an action plan for
developing capacity for collaborative comparative effective-
ness research in palliative care.
Funding
Financial support was provided by the National Palliative
Care Research Center.
Results
The meeting opened with a goal alignment exercise and
brainstorming session, followed by 16 brief presentations
with question-and-answer periods (Table 1).
Participants unanimously agreed to form a research coop-
erative group broadly focused on studies relevant to palliative
care, called the Palliative Care Research Cooperative (PCRC).
Its mission is to decrease the burden of suffering and to im-
prove outcomes for patients with advanced life-limiting ill-
ness and their families. The group delineated core principles
that will guide PCRC development (Table 2).
Presentations by Australian and Canadian colleagues de-
scribed the experiences of two successful cooperative groups.
These individuals offered to share their organizations’ policies
and structures (e.g., bylaws, forms, processes), so that the
experiences of established networks might inform PCRC de-
velopment. Development must address: processes, including
those for adding new members, prioritizing research topics,
collaboratively developing a protocol, and initiating a clinical
trial; governance, including data ownership, data sharing,
and dispute resolution; standardization of research proce-
dures, e.g., through data collection forms, recruitment and
consenting protocols, inclusion of minorities andwomen, and
standardized human subject protection; data management,
covering data collection, transfer, storage, quality assurance,
management, aggregation, and extraction; and analysis, in-
cluding statistical support and reporting. A set of PCRC op-
erating procedures will address these issues. The definition of
members’ roles, and description of different levels of investi-
gator and site involvement, represent additional topics for
clarification.
An initial PCRC membership, comprising all participants
in the Denver meeting, was agreed upon. Additional mem-
bers will be included to extend the reach of the network and
the availability of research infrastructure for palliative care
investigators. The PCRC will emphasize education through
mentoring junior investigators and helping to build skills
among staff at research-naı¨ve clinical sites.
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Dilts et al. 23 underscored the importance of an early ‘‘win’’
for maintaining initial momentum and setting an enduring,
productive course for a cooperative group. PCRC founding
members therefore decided to launch the PCRC with a dem-
onstration clinical trial that is straightforward to implement
and possible to complete within a short timeframe—but also
likely to definitively answer an important clinical question.
The group chose discontinuation of medications for comorbid
chronic disease, among patients with advanced life-limiting
illness, as a compelling and clinically meaningful issue, one
arising frequently in practice, and one for which genuine
clinical uncertainty exists.
The first trial, envisioned as a step toward operationalizing
a theoretical framework for managing comorbid illnesses at
the end of life,31,32 is a medication discontinuation trial fo-
cused on statins. Among the most prescribed medications in
the world, statins are commonly encountered in palliative
care. Because more than 25% of Medicare beneficiaries take a
statin,33 any change in prescribing practice could dramatically
impact health resource utilization. While the benefit of statins
for patients with cardiovascular risk, but without a defined
short survival prognosis, is well-demonstrated,34–36 the ben-
efit versus cost/risk of this medication in patients with an
estimated prognosis of less than 6 months remains unknown.
Statins can contribute to illness burden. Up to 8% of patients
taking statins report gastrointestinal side effects37; myopathy
is the most common serious adverse effect.35,38,39 Conversely,
the safety of statin discontinuation is a critical concern; ob-
servational studies suggest that 1-year mortality may be
higher in acute myocardial infarction survivors whose statins
Table 1. Palliative Care Research Cooperative January 2010 Meeting Participants and Presentations
Name Institution Presentations
Amy Abernethy
(Host)a
Duke University Medical Center Parallel stories from U.S. hospice and palliative care
and lessons learned; Moving from outcomes to data
collection
Ethan Basch Memorial Sloan Kettering Cancer Center Adverse events as outcomes, or vice versa?
Janet Bull Four Seasons What does cooperative research require? And offer?
David Cella Northwestern University Medical Center
Charlie Cleelanda M.D. Anderson Cancer Center Current and previous initiatives for joint research in
palliative care and symptom management; out-
comes measurement in disadvantaged and under-
served populations
David Currowa Flinders University (Adelaide, Australia) Australian model for a palliative care clinical studies
collaborative
Diane Fairclougha University of Colorado Denver Medical
Center
Laura Hansona University of North Carolina, Chapel
Hill
What does cooperative research require? And offer?
Josh Hausera Northwestern University Medical Center
Paul Hutson University of Wisconsin
Jean Kutner (Host)a Univ. of Colorado Denver Medical
Center
What makes a population-based research network?
Linda Lloyda San Diego Hospice and The Institute for
Palliative Medicine
Janelle McCallum Denver Hospice
Jeri Millera National Institutes of Health
R. Sean Morrisona Mount Sinai School of Medicine National Palliative Care Research Center and The
Pepper Center
Ann O’Maraa National Institutes of Health A Brief History of the Oncology Cooperative Groups;
IRB Issues; National initiatives related to PRO’s and
other palliative care-related outcomes
Shirley Otis-Greena City of Hope City of Hope palliative care research and education
Steve Pantilat University of California at San Francisco
Russ Portenoy Beth Israel Medical Center
Christine Ritchiea University of Alabama at Birmingham Research at the UAB School of Medicine Center for
Palliative Care
Graeme Rockera Dalhousie University Canadian model for a palliative care clinical studies
collaborative
Jeff Sloana Mayo Clinic PRO Advances in Palliative Care
David Westa University of Colorado Denver
Jane Wheelera Duke University Medical Center
Yousuf Zafara Duke University Medical Center
aParticipated in-person vs. via videoconferencing.
IRB, Institutional Review Board.
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are discontinued.40 The effect of statin discontinuation on
other outcomes important in palliative care, such as patient
burden, quality of life, and performance status, is also unclear.
Although an enlarging literature, predominantly in palliative
care journals, supports discontinuation of medications, spe-
cifically statins, in end-stage disease,41 the balance of medi-
cation efficacy versus burden has yet to be defined in clinical
studies.
With statin discontinuation as the agreed topic for a PCRC
demonstration trial,32 members worked together to develop
an application for a federal grant, submitted to the NIH in
March 2010; the National Institute of Nursing Research has
awarded funding.
Discussion
The need for a concerted approach to evidence develop-
ment in palliative care is well accepted. What has been less
clear is the best way to develop that evidence base given the
barriers to research in palliative care, disparate pockets of
research expertise, and a majority of clinical sites not con-
versant with research processes. A cooperative group frame-
work may help overcome many obstacles to palliative care
research, such as lack of standardized definitions and pro-
cesses, small populations in clinical trial sites, and uneven
distribution of expertise.
Cooperative groups have met with varying levels of suc-
cess. The PCRC is endeavoring to learn from the experiences
of other cooperative groups. Likely to support its success are:
the coalescence of a sizeable group of committed, experienced
investigators who have a history of and commitment to
working together; agreement on the cooperative group’s
purposes, parameters, and first steps; a pragmatic approach
focused on prioritizing studies and efficiently generating re-
sults that can be applied to current clinical practice, and; a
design intended to support learning-through-doing and iter-
ative adaptation. Streamlining research activation processes
and minimizing the layers of bureaucracy will help to avoid
the roadblocks and delays encountered by other cooperative
groups. Dilts et al.23,24 suggest several procedures for over-
coming barriers, which the PCRC plans to adopt: process
mapping, to identify and eliminate those steps that do not add
value to the protocol; inclusion of operational complexity,
alongside scientific merit, in study review criteria, and; re-
ducing study activation time through changes to concept or
protocol. Because studies that fare poorly on initial scientific
review exhibit disappointing long-term success, they suggest
winnowing out these unlikely-to-succeed projects in favor of
other, potentially more productive, endeavors. A focus on
practicality, feasibility, and efficiency is key to timely com-
pletion of collaborative studies.
Overall, palliative care is ripe for research development but
under-resourced for research infrastructure and not savvy in
research processes. Hence, a PCRC data collection strategy
must be pragmatic, inexpensive, and convenient in commu-
nity-based as well as academic settings. To allow for partici-
pation of smaller and nonacademic sites, total costs of
research need to beminimized through choice of study design
andmethodology; fundingwill likely need to be secured from
the NIH, to sufficiently support infrastructure development
and studies. Care should be taken to identify best items, in-
struments, measures, and outcomes – matched to the research
question and to practical considerations. By incorporating
expertise in patient-reported outcomes at the outset, the
PCRC is making a commitment to research that directly ad-
dresses the concerns of people with complex and/or life-
limiting illness. The most consistent hurdle to palliative care
clinical trials is participant recruitment; hence, the first PCRC
trial will incorporate a careful recruitment program based
upon prior successful models in palliative care.42 Other con-
cerns requiring careful attention are participant burden,
clarity of outcomes, data management, missing data, and
ethical issues.
Challenges that may limit the success of the PCRC group
approach include: (1) its inherent risk, in that we cannot know
in advance if the PCRC is a feasible structure; (2) the possi-
bility that unique vulnerabilities of the population and human
subjects protections concerns may limit feasibility of a multi-
site approach; (3) the possibility of lack of funding; (4) the
possibility that only large research institutions will partici-
pate, thereby potentially limiting the generalizability of re-
sults, failing to build research capacity more broadly, and
omitting valuable perspectives from agenda setting and pri-
oritization; (5) the need for strong leadership, balanced
Table 2. Palliative Care Research Cooperative Group Core Principles
 Active interdisciplinary membership, with an understanding that membership decisions will reflect an inclusive rather than
exclusive orientation.
 Commitment to shared research purposes, including development of meaningful and sustainable palliative care research,
patient-focused inquiries and methods, and use of measurable outcomes valued by patients, investigators, regulators, and
funders.
 Heterogeneity of sites, i.e., participation of sites with diverse skills, demographics, practice patterns, and healthcare delivery
systems, to ensure the PCRC’s ability to meet the needs of diverse research studies.
 Development of research capacity in participating sites, to upskill sites through increasing their knowledge of research
methodology.
 Standardization of methodologies, such as study procedures, consenting, and data collection and management.
 Agility, i.e., ability to respond efficiently to requests of investigators, government sponsors, and industry.
 Responsiveness to regulatory and ethical requirements, including human subject protections.
 Focus on translation, i.e., connecting innovative ideas with clinically relevant and measurable outcomes; rapid
implementation of research results to effect change.
 Engagement in education, to energize and train future researchers in palliative care.
 Generation of actionable results that can inform health policy.
PCRC, Palliative Care Research Cooperative.
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against the need for broad-based participation; (6) the po-
tential for unanticipated problems to impede the organiza-
tion’s function; and (7) the potential for individual goals to
overshadow collaborative intentions.
Our proactive responses to these limitations are as follows.
(1,2) Inherent risk is a necessary condition, but not a reason to
forego the opportunity, provided we take conscious steps to
make the PCRC feasible. (3) Funding constraints are a valid
concern, and one reason for creating the PCRC. We argue that
studies conducted in this collaborative, multi-institutional
context, as part of a larger national agenda, have a better
chance of securing funding than do stand-alone and/or single-
institution studies. (4) The group is committed to inclusion of
diverse sites, and regular discussion of membership, with
strategies developed to promote heterogeneity of research
participants. (5) The first PCRC trial highlights the need for a
core team of leaders on any given study, yet this functional
requirement does not obviate the participation of multiple
other members. A focus on the core principles of active inter-
disciplinary participation and commitment will remind those
most active in the PCRC to continue to reach out and engage
additional members. (6) Unanticipated problems are best re-
solved by a governance committee and/or steering committee.
Structures will be created that can expeditiouslywork through
roadblocks, with a focus on timeliness, research completion,
delivery, and translation. (7) PCRC investigators have made a
group commitment to monitor and remedy such problems.
Through a deliberated and inclusive process, the PCRC
was established and the first study protocol submitted
for funding to the NIH. Our next steps include developing
a 5-year agenda of studies, drafting standard operating pro-
cedures, and cultivating collaborative relations with profes-
sional associations, potential funders, and relevant national
entities. We welcome input from our colleagues both within
and outside palliative care. The field of palliative care will
require novel approaches to evidence development; the PCRC
seeks to fill an important void in current research, and to
prepare future investigators to advance the field and con-
tribute to the evidence base, toward the ultimate goal of im-
proving care for patients with life-threatening illness.
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